Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

類似資料

• Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti‐adalimumab in patients with inflammatory diseases
  著者:: Kneepkens, Eva L., 等
  出版事項: (2017)
• Immunogenicity of TNF-Inhibitors
  著者:: Atiqi, Sadaf, 等
  出版事項: (2020)
• The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
  著者:: Geurts-Voerman, Gerlienke E., 等
  出版事項: (2020)
• High levels of human anti‐human antibodies to adalimumab in a patient not responding to adalimumab treatment
  著者:: Bartelds, G M, 等
  出版事項: (2006)
• Clinical response to adalimumab: relationship to anti‐adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
  著者:: Bartelds, Geertje M, 等
  出版事項: (2007)